Home / Market News / $TDOC
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Oppenheimer Adjusts Teladoc Health Price Target to $10 From $7

Nov 2, 2026, 10:33 PM UTC · Primary ticker $TDOC

Oppenheimer has increased its price target for Teladoc Health (TDOC) from $7 to $10, while reiterating an 'Outperform' rating. This indicates a more positive outlook from the firm regarding Teladoc's future stock performance, potentially influencing investor sentiment.

Oppenheimer, a prominent financial firm, has adjusted its price target for Teladoc Health (TDOC) upwards from $7 to $10, while maintaining an 'Outperform' rating. This action signals increased confidence from the analyst in Teladoc's future prospects and valuation. For traders, this could lead to short-term positive momentum for TDOC stock as investors react to the upgraded outlook. In the long term, sustained positive analyst sentiment, coupled with strong company performance, could support further stock appreciation. The key opportunity for traders lies in potentially buying into a stock with renewed analyst backing, though the risk remains that the market may not fully align with Oppenheimer's revised valuation.

$TDOC positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.